AccuStem Sciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, disclosing a net loss of $1,869,895 for the three months ended September 30, 2026, driven in part by a $1,500,000 acquired in-process research and development expense.

Key Highlights

  • Net loss for Q3 2026: $1,869,895, compared to $399,897 in Q3 2025, according to the filing.
  • Nine-month net loss: $2,608,351 for the nine months ended September 30, 2026, versus $1,241,708 for the same period in 2025.
  • Acquired in-process R&D charge: $1,500,000 recorded in both Q3 2026 and the nine-month period ended September 30, 2026.
  • Accumulated deficit: $12,391,494 as of September 30, 2026, up from $9,783,143 as of December 31, 2025.
  • Total shareholders' equity: Negative $5,980,129 as of September 30, 2026, compared to negative $3,401,625 as of December 31, 2025.
  • Shares outstanding: 16,072,267 shares of common stock as of November 20, 2026.
  • Related party payable: $5,363,673 as of September 30, 2026, up from $4,222,838 as of December 31, 2025.

AccuStem Sciences Reports Q3 2026 Financials with Large IPR&D Expense and Growing Deficit

AccuStem Sciences, Inc. (OTCQB:ACUT), a Delaware-incorporated company headquartered at 420 Lexington Avenue, Suite 1402, New York, NY 10001, reported its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026. The company disclosed a net loss of $1,869,895 for Q3 2026, compared to a net loss of $399,897 in the same quarter of 2025. The filing attributed a significant portion of the quarterly loss to a $1,500,000 acquired in-process research and development expense recorded in the quarter, which did not appear in the prior-year period.

According to the filing, total operating expenses for the three months ended September 30, 2026 were $1,869,895, comprising $14,359 in research and development expenses, $1,500,000 in acquired in-process research and development expense, and $355,536 in general and administrative expenses. For the nine-month period, total operating expenses reached $2,608,351. The company reported a basic and diluted net loss per share of $0.12 for Q3 2026, compared to $0.02 in Q3 2025, based on a weighted average of 16,072,267 common shares outstanding.

The balance sheet as of September 30, 2026 showed total assets of $83,201, consisting primarily of cash of $15,303 and prepaid expenses of $67,898. Total liabilities stood at $6,063,330, with related party payable representing the largest component at $5,363,673. The company reported no other non-current assets as of September 30, 2026, compared to $1,500,000 at December 31, 2025. Share-based compensation of $29,847 was recorded for the nine months ended September 30, 2026. The company disclosed it is a smaller reporting company and an emerging growth company.

What Was Disclosed

AccuStem Sciences filed its quarterly report covering the period ended September 30, 2026, disclosing a net loss of $1,869,895 for the quarter and $2,608,351 for the nine-month period, an accumulated deficit of $12,391,494, and total shareholders' equity of negative $5,980,129.